Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 0.7% After Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares were down 0.7% during trading on Monday following insider selling activity. The stock traded as low as $6.03 and last traded at $6.07. Approximately 1,184,366 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 5,826,398 shares. The stock had previously closed at $6.11.

Specifically, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the transaction, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,697,960.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $6.22, for a total value of $71,200.34. Following the sale, the director now owns 7,098,428 shares of the company’s stock, valued at $44,152,222.16. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

RXRX has been the topic of several research analyst reports. Jefferies Financial Group lowered their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Needham & Company LLC cut their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, KeyCorp decreased their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Up 4.2 %

The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -3.91 and a beta of 0.80. The firm has a 50 day simple moving average of $6.79 and a 200-day simple moving average of $7.98.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The company had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company’s revenue was up 30.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.38) EPS. On average, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Large investors have recently modified their holdings of the business. Green Alpha Advisors LLC increased its holdings in Recursion Pharmaceuticals by 2.9% during the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock worth $427,000 after purchasing an additional 1,800 shares in the last quarter. Wedmont Private Capital increased its position in Recursion Pharmaceuticals by 11.8% during the first quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock worth $172,000 after buying an additional 2,000 shares during the last quarter. Interchange Capital Partners LLC lifted its holdings in Recursion Pharmaceuticals by 7.3% during the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after purchasing an additional 2,349 shares during the last quarter. Amalgamated Bank grew its stake in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in shares of Recursion Pharmaceuticals in the first quarter valued at approximately $26,000. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.